|
WO2021077181A1
|
|
A cancer diagnostic
|
|
WO2021077175A1
|
|
Adoptive immunotherapy
|
|
WO2021068040A1
|
|
Targeting epha3 and uses thereof
|
|
WO2021042163A1
|
|
Methods and agents for determining patient status
|
|
WO2021014213A1
|
|
Immunotherapy for polyomaviruses
|
|
WO2020237320A1
|
|
Anti-gal9 immune-inhibiting binding molecules
|
|
WO2020243623A1
|
|
Activating anti-gal9 binding molecules
|
|
WO2020232510A1
|
|
Method of treatment
|
|
WO2020232512A1
|
|
Microglial cells and methods of use thereof
|
|
WO2020172715A1
|
|
Cells, compositions and methods for enhancing immune function
|
|
WO2020113274A1
|
|
Rank antagonists and uses therefor
|
|
WO2020107073A1
|
|
Inhibiting inflammation
|
|
WO2020087130A1
|
|
Prognosis and treatment of inflammatory bowel disease
|
|
WO2020082130A1
|
|
T-cell receptors and uses thereof
|
|
WO2020047604A1
|
|
Biomarkers for cancer therapy
|
|
WO2020028957A1
|
|
Skeletal muscle cell maturation
|
|
EP3807423A2
|
|
Viral detection assay
|
|
CA3100420A1
|
|
Adoptive t-cell therapy for cmv infection and cmv-associated diseases
|
|
WO2020186283A1
|
|
Cardiomyocyte proliferation
|
|
AU2019271304A1
|
|
Modulating immune responses
|
